Open-label, uncontrolled, before-and-after study of GGS in multifocal motor neuropathy (MMN) (Phase 3 study)
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Immune globulin (Primary)
- Indications Multifocal motor neuropathy
- Focus Therapeutic Use
- Sponsors Teijin Pharma
- 19 Jun 2018 Status changed from recruiting to completed.
- 01 May 2017 Planned End Date changed from 31 Mar 2016 to 30 Apr 2018.
- 09 Jun 2016 New trial record